Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short term Debt (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Short term Debt for 9 consecutive years, with $26.2 million as the latest value for Q1 2025.

  • Quarterly Short term Debt changed N/A to $26.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Mar 2025, changed N/A year-over-year, with the annual reading at $13.6 million for FY2024, 312.73% up from the prior year.
  • Short term Debt hit $26.2 million in Q1 2025 for Coherus Oncology, up from $13.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $26.2 million in Q1 2025 to a low of $90000.0 in Q2 2023.
  • Historically, Short term Debt has averaged $9.5 million across 4 years, with a median of $9.2 million in 2024.
  • Biggest YoY gain for Short term Debt was 10124.44% in 2024; the steepest drop was 127.77% in 2024.
  • Year by year, Short term Debt stood at $17.3 million in 2021, then tumbled by 80.93% to $3.3 million in 2023, then soared by 312.73% to $13.6 million in 2024, then surged by 92.57% to $26.2 million in 2025.
  • Business Quant data shows Short term Debt for CHRS at $26.2 million in Q1 2025, $13.6 million in Q4 2024, and $9.2 million in Q3 2024.